April 6, 2020
Drug for Head Lice Treatment can Kill Cells from COVID-19
A drug they utilize in treating head lice can potential kill the cells caused by the Novel Coronavirus 2019 (COVID-19) as explained by the researchers from Monash University.
The anti-parasite drug is what they call the Ivermectin and the study is now ongoing.
From the news reported online through dailymail.co.uk, scientists from the Monash University in Australia revealed that there is a possibility that the anti-parasite drug known as the Ivermectin can kill the COVID-19 cells and help in treating the infected patients.
During their actual test, the drug managed to eliminate the cells in the span of 48 hours and this kind of option is easily accessible in various pharmacies. As detailed by the news as well, research experts had proved the effectiveness of the drug is treating Zika virus, Influenza, dengue and HIV/AIDS.
Again, this particular drug is use for killing head lice and it will be a breakthrough if it works.
Based on the conducted study led by the research experts or scientists from the Australian-based University, a single dosage of the Ivermectin can already prevent the development of the cell from the SARS-CoV-2 virus.
“We found that even a single dose could essentially remove all viral RNA (effectively removed all genetic material of the virus) by 48 hours and that even at 24 hours there was a really significant reduction in it,” said Dr Kylie Wagstaff as published through thenewdaily.com.au.
“In times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world then that might help people sooner,” the doctor also stated.
Although they cannot yet determine on how the head lice drug kills off the COVID-19 virus, it is capable of dampening the cells and this leads to eliminating them. Besides killing the head lice, this kind of drug can also eliminate other parasites like scabies and River Blindness.
The next procedure that the scientists want to study is the right amount of drug or level of dose they need to use for the human body.
In addition to this, there is a need for sufficient funding before they can start the pre-clinical tests and clinical trials. This is important before they can make the availability of the developed vaccine becomes widely ready.
Dr. Kylie Wagstaff is from the Monash Biomedicine Discovery Institute.
The new study about using Ivermectin is a joint effort between the Monash Biomedicine Discovery Institute and Peter Doherty Institute of Infection and Immunity, both based in Australia. The findings they have became available through Antiviral Research’s publication.
The Food and Drug Administration (FDA) recognizes the anti-parasite drug and if the ongoing study becomes successful for COVID-19 treatment, this will be a huge help in saving thousands of sufferers across the globe.
As detailed through worldmeters.info as of April 6, 2020, the COVID-19 cases worldwide is already 1,274,199. The death toll is at 69,468 and the patients who recovered already are at 264,833.
Almost all nations are continuously searching for the best possible treatments to defeat such pandemic virus.